



**PRESS RELEASE**

**Nyxoah to present at the Oppenheimer 31<sup>st</sup> Annual Healthcare Conference**

**Mont-Saint-Guibert, Belgium – 24<sup>th</sup> February 2021** – Nyxoah SA (Euronext: NYXH) (“Nyxoah” or the “Company”), a health-technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announces the participation of its management team in the Oppenheimer 31<sup>st</sup> Annual Healthcare Conference on Wednesday, March 17, 2021. Olivier Taelman, CEO of Nyxoah, will represent the Company in a virtual session scheduled to begin at 8:40 AM (ET).

A live webcast of Nyxoah’s session will be available on the Events section of the Company’s investor website at <https://investors.nyxoah.com/events> or can be accessed via the following link:

[Link to webcast](#)

An archived replay of the presentation will be available for 90 days after the conference on Nyxoah’s investor website.

**- ENDS -**

**For further information, please contact:**

**Nyxoah**

Milena Venkova, Corporate Communications Manager

[milena.venkova@nyxoah.com](mailto:milena.venkova@nyxoah.com)

+32 490 11 93 57

**About Nyxoah**

Nyxoah is a healthtech company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio<sup>®</sup> system, a CE-validated, patient-centered, next generation hypoglossal neurostimulation therapy for

OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk<sup>1</sup> and comorbidities including cardiovascular diseases, depression and stroke.

Following successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio<sup>®</sup> system received its European CE Mark in March 2019. The Company is currently conducting the BETTER SLEEP study in Australia and New Zealand for therapy indication expansion, the DREAM IDE pivotal study for FDA approval and a post-marketing EliSA study in Europe to confirm the long-term safety and efficacy of the Genio<sup>®</sup> system.

For more information, please visit [www.nyxoah.com](http://www.nyxoah.com).

**Caution** – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

---

<sup>1</sup> Young T. et al: Sleep Disordered Breathing and Mortality: Eighteen-Year Follow-up of the Wisconsin Sleep Cohort, *Sleep*. 2008 Aug 1; 31(8): 1071–1078.